Related references
Note: Only part of the references are listed.Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
Selma Ugurel et al.
EUROPEAN JOURNAL OF CANCER (2020)
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
Teresa Amaral et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
Ricarda Rauschenberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V. Long et al.
LANCET ONCOLOGY (2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
Joanna Mangana et al.
MELANOMA RESEARCH (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment of melanoma brain metastases
Simone M. Goldinger et al.
CURRENT OPINION IN ONCOLOGY (2016)
Radiotherapy Complements Immune Checkpoint Blockade
Shin Foong Ngiow et al.
CANCER CELL (2015)
Genomic Classification of Cutaneous Melanoma
Rehan Akbani et al.
CELL (2015)
Evolving treatment options for melanoma brain metastases
Thankamma Ajithkumar et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
Tessa Kennedy-Martin et al.
TRIALS (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Reinhard Dummer et al.
EUROPEAN JOURNAL OF CANCER (2014)
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival
Stefania Vecchio et al.
MELANOMA RESEARCH (2014)
Clinical Variables and Primary Tumor Characteristics Predictive of the Development of Melanoma Brain Metastases and Post-Brain Metastases Survival
Jan Zakrzewski et al.
CANCER (2011)
Prognostic Factors for Survival in Melanoma Patients With Brain Metastases
Michael A. Davies et al.
CANCER (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Determinants of outcome in melanoma patients with cerebral metastases
KM Fife et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
